Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Overview Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development Celldex Therapeutics Inc Elsalys Biotech SAS Ignyta Inc Qurient Co Ltd Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Drug Profiles Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Inhibit TYRO-3 for Bladder Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress ELB-031 - Drug Profile Product Description Mechanism Of Action R&D Progress Q-701 - Drug Profile Product Description Mechanism Of Action R&D Progress RNAi Oligonucleotide to Inhibit TYRO-3 for Bladder Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress RXDX-106 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit TYRO3 for Bladder Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Dormant Products Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Product Development Milestones Featured News & Press Releases Dec 29, 2017: Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Celldex Therapeutics Inc, H1 2018 Pipeline by Elsalys Biotech SAS, H1 2018 Pipeline by Ignyta Inc, H1 2018 Pipeline by Qurient Co Ltd, H1 2018 Dormant Projects, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Celldex Therapeutics Inc Elsalys Biotech SAS Ignyta Inc Qurient Co Ltd